IKT
NASDAQ · Biotechnology
Inhibikase Therapeutics Inc
$2.05
+0.00 (+0.00%)
Open$2.04
Previous Close$2.05
Day High$2.05
Day Low$2.02
52W High$2.61
52W Low$1.33
Volume—
Avg Volume706.9K
Market Cap287.44M
P/E Ratio—
EPS$-0.50
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,266.3% upside
Current
$2.05
$2.05
Target
$28.01
$28.01
$19.41
$28.01 avg
$39.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 78.22M | 74.95M | 61.90M |
| Net Income | 4.38M | 5.16M | 3.75M |
| Profit Margin | 5.6% | 6.9% | 6.1% |
| EBITDA | 7.32M | 7.08M | 6.90M |
| Free Cash Flow | 4.21M | 5.04M | 4.89M |
| Rev Growth | +8.7% | +15.3% | -5.1% |
| Debt/Equity | 0.35 | 0.45 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |